The Management of Bipolar Disorder During and After Pregnancy

Chapter
Part of the Milestones in Drug Therapy book series (MDT)

Abstract

This chapter will discuss the issues of psychiatric management of bipolar disorder (BD) both during and after pregnancy. The risks and benefits of medication use during pregnancy will be discussed along with the risks of discontinuation of medications for pregnancy. Pharmacological treatments will be discussed in detail. The postpartum time period and its risks for depression, mania, and psychosis will be described, and recommendations for management during this critical time period will be detailed. Medication use during breastfeeding will also be discussed.

Keywords

Pregnancy Postpartum depression Postpartum psychosis 

References

  1. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation (2008). Obstet Gynecol 111(4):1001–1020Google Scholar
  2. Addis A, Koren G (2000) Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 30(1):89–94PubMedCrossRefGoogle Scholar
  3. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J (1996) Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 153(5):592–606PubMedCrossRefGoogle Scholar
  4. Alwan S, Friedman JM (2009) Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 23(6):493–509PubMedCrossRefGoogle Scholar
  5. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356(26):2684–2692PubMedCrossRefGoogle Scholar
  6. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A, Friedman JM (2010) Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 203(1):52 e51–56.Google Scholar
  7. American Academy of Pediatrics (2000) Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Committee on Drugs. Pediatrics 105(4 Pt 1):880–887Google Scholar
  8. Andersson L, Sundstrom-Poromaa I, Bixo M, Wulff M, Bondestam K, aStrom M (2003) Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol 189(1):148–154PubMedCrossRefGoogle Scholar
  9. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R (2009) Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 18(3):246–252PubMedCrossRefGoogle Scholar
  10. Ashman SB, Dawson G, Panagiotides H, Yamada E, Wilkinson CW (2002) Stress hormone levels of children of depressed mothers. Dev Psychopathol 14(2):333–349PubMedCrossRefGoogle Scholar
  11. Austin MP (1992) Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry 161:692–694PubMedCrossRefGoogle Scholar
  12. Barnes TR (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 25(5):567–620PubMedCrossRefGoogle Scholar
  13. Bergink V, Bouvy PF, Vervoort JS, Koorengevel KM, Steegers EA, Kushner SA (2012) Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 169(6):609–615PubMedCrossRefGoogle Scholar
  14. Berle JO, Spigset O (2011) Antidepressant use during breastfeeding. Curr Womens Health Rev 7(1):28–34PubMedPubMedCentralCrossRefGoogle Scholar
  15. Black RA, Hill DA (2003) Over-the-counter medications in pregnancy. Am Fam Physician 67(12):2517–2524PubMedGoogle Scholar
  16. Bogen DL, Sit D, Genovese A, Wisner KL (2012) Three cases of lithium exposure and exclusive breastfeeding. Arch Womens Ment Health 15(1):69–72PubMedPubMedCentralCrossRefGoogle Scholar
  17. Brennan PA, Pargas R, Walker EF, Green P, Newport DJ, Stowe Z (2008) Maternal depression and infant cortisol: influences of timing, comorbidity and treatment. J Child Psychol Psychiatry 49(10):1099–1107PubMedPubMedCentralCrossRefGoogle Scholar
  18. Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, Garcia-Finana M, Kneen R, Lucas SB, Shallcross R, Baker GA (2013) The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry 84(6):637–643PubMedPubMedCentralCrossRefGoogle Scholar
  19. Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC (2013) Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 14:38PubMedPubMedCentralCrossRefGoogle Scholar
  20. Byatt N, Deligiannidis KM, Freeman MP (2013) Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 127(2):94–114PubMedCrossRefGoogle Scholar
  21. Campbell SB, Cohn JF (1991) Prevalence and correlates of postpartum depression in first-time mothers. J Abnorm Psychol 100(4):594–599PubMedCrossRefGoogle Scholar
  22. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354(6):579–587PubMedCrossRefGoogle Scholar
  23. Christensen J, Gronborg TK, Sorensen MJ, Schendel D, Parner ET, Pedersen LH, Vestergaard M (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309(16):1696–1703PubMedPubMedCentralCrossRefGoogle Scholar
  24. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A (2005) Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 192(3):932–936PubMedCrossRefGoogle Scholar
  25. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL (2013) Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 170(11):1240–1247PubMedPubMedCentralCrossRefGoogle Scholar
  26. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML (1994) A reevaluation of risk of in utero exposure to lithium. JAMA 271(2):146–150PubMedCrossRefGoogle Scholar
  27. Cohen LS, Sichel DA, Robertson LM, Heckscher E, Rosenbaum JF (1995) Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 152(11):1641–1645PubMedCrossRefGoogle Scholar
  28. Cohen LS, Wang B, Nonacs R, Viguera AC, Lemon EL, Freeman MP (2010) Treatment of mood disorders during pregnancy and postpartum. Psychiatr Clin North Am 33(2):273–293PubMedCrossRefGoogle Scholar
  29. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM (2007) Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16(5):474–484PubMedCrossRefGoogle Scholar
  30. Communication FDS (2011) Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. http://www.fda.gov/Drugs/DrugSafety/ucm243903.htm-sa. Accessed 28 Apr 15
  31. Coppola D, Russo LJ, Kwarta RF Jr, Varughese R, Schmider J (2007) Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 30(3):247–264PubMedCrossRefGoogle Scholar
  32. Cox JL, Murray D, Chapman G (1993) A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry 163:27–31PubMedCrossRefGoogle Scholar
  33. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V (2011) Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68(11):1104–1112PubMedCrossRefGoogle Scholar
  34. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY (2010) Teratology and medications that affect the fetus. In: Williams obstetrics. McGraw Hill, New York, pp 312–333Google Scholar
  35. Cunnington M, Tennis P (2005) Lamotrigine and the risk of malformations in pregnancy. Neurology 64(6):955–960PubMedCrossRefGoogle Scholar
  36. Davis EP, Glynn LM, Dunkel Schetter C, Hobel C, Chicz-Demet A, Sandman CA (2005) Corticotropin-releasing hormone during pregnancy is associated with infant temperament. Dev Neurosci 27(5):299–305PubMedCrossRefGoogle Scholar
  37. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Platt R (2007) Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 16(10):1086–1094PubMedCrossRefGoogle Scholar
  38. DeVane CL, Stowe ZN, Donovan JL, Newport DJ, Pennell PB, Ritchie JC, Owens MJ, Wang JS (2006) Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 20(4 Suppl):54–59PubMedCrossRefGoogle Scholar
  39. Diego MA, Field T, Hernandez-Reif M, Cullen C, Schanberg S, Kuhn C (2004) Prepartum, postpartum, and chronic depression effects on newborns. Psychiatry 67(1):63–80PubMedCrossRefGoogle Scholar
  40. Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT (2008) Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 71(10):714–722PubMedCrossRefGoogle Scholar
  41. Einarson A, Boskovic R (2009) Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 15(3):183–192PubMedCrossRefGoogle Scholar
  42. Einarson TR, Einarson A (2005) Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 14(12):823–827PubMedCrossRefGoogle Scholar
  43. Einarson A, Einarson TR (2009) Maternal use of antipsychotics in early pregnancy: little evidence of increased risk of congenital malformations. Evid Based Ment Health 12(1):29PubMedCrossRefGoogle Scholar
  44. Essex MJ, Klein MH, Cho E, Kalin NH (2002) Maternal stress beginning in infancy may sensitize children to later stress exposure: effects on cortisol and behavior. Biol Psychiatry 52(8):776–784PubMedCrossRefGoogle Scholar
  45. Fejzo MS, Magtira A, Schoenberg FP, MacGibbon K, Mullin P, Romero R, Tabsh K (2013) Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 170(1):71–76PubMedPubMedCentralCrossRefGoogle Scholar
  46. Field T, Diego M, Hernandez-Reif M (2006) Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 29(3):445–455PubMedCrossRefGoogle Scholar
  47. Field T, Diego M, Hernandez-Reif M (2010) Prenatal depression effects and interventions: a review. Infant Behav Dev 33(4):409–418PubMedPubMedCentralCrossRefGoogle Scholar
  48. Frank E, Kupfer DJ, Jacob M, Blumenthal SJ, Jarrett DB (1987) Pregnancy-related affective episodes among women with recurrent depression. Am J Psychiatry 144(3):288–293PubMedCrossRefGoogle Scholar
  49. Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, Han JY, Matsui D, Etwell F, Einarson TR, Koren G, Einarson A (2013) Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 80(17):1565–1570PubMedPubMedCentralCrossRefGoogle Scholar
  50. Gentile S (2004) Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother 38(7–8):1265–1271PubMedCrossRefGoogle Scholar
  51. Gentile S (2008) Infant safety with antipsychotic therapy in breast-feeding: a systematic review. J Clin Psychiatry 69(4):666–673PubMedCrossRefGoogle Scholar
  52. Gentile S (2010) Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 36(3):518–544PubMedCrossRefGoogle Scholar
  53. Ghaemi SN, Boiman EE, Goodwin FK (2000) Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 61(10):804–808, quiz 809PubMedCrossRefGoogle Scholar
  54. Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA (2014) Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf 13(12):1667–1698PubMedPubMedCentralCrossRefGoogle Scholar
  55. Grace SL, Evindar A, Stewart DE (2003) The effect of postpartum depression on child cognitive development and behavior: a review and critical analysis of the literature. Arch Womens Ment Health 6(4):263–274PubMedCrossRefGoogle Scholar
  56. Habermann F, Fritzsche J, Fuhlbruck F, Wacker E, Allignol A, Weber-Schoendorfer C, Meister R, Schaefer C (2013) Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 33(4):453–462PubMedCrossRefGoogle Scholar
  57. Hageman JR, Adams MA, Gardner TH (1984) Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis, and management. Am J Dis Child 138(6):592–595PubMedCrossRefGoogle Scholar
  58. Halligan SL, Herbert J, Goodyer IM, Murray L (2004) Exposure to postnatal depression predicts elevated cortisol in adolescent offspring. Biol Psychiatry 55(4):376–381PubMedCrossRefGoogle Scholar
  59. Hanley GE, Oberlander TF (2014) The effect of perinatal exposures on the infant: antidepressants and depression. Best Pract Res Clin Obstet Gynaecol 28(1):37–48PubMedCrossRefGoogle Scholar
  60. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR (2005) Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 39(5):803–809PubMedCrossRefGoogle Scholar
  61. Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA (2007) Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120(2):e272–e282PubMedCrossRefGoogle Scholar
  62. Holmes LB, Hernandez-Diaz S (2012) Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol 94(8):599–606PubMedCrossRefGoogle Scholar
  63. Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, Wyszynski DF (2008) Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 70(22 Pt 2):2152–2158PubMedCrossRefGoogle Scholar
  64. Huybrechts KF, Sanghani RS, Avorn J, Urato AC (2014) Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One 9(3):e92778PubMedPubMedCentralCrossRefGoogle Scholar
  65. Huybrechts KF, Bateman BT, Palmsten K, Desai RJ, Patorno E, Gopalakrishnan C, Levin R, Mogun H, Hernandez-Diaz S (2015) Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313(21):2142–2151PubMedPubMedCentralCrossRefGoogle Scholar
  66. Hviid A, Melbye M, Pasternak B (2013) Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med 369(25):2406–2415PubMedCrossRefGoogle Scholar
  67. Iqbal MM, Sobhan T, Ryals T (2002) Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 53(1):39–49PubMedCrossRefGoogle Scholar
  68. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, Donnenfeld AE, Rieder M, Santelli R, Smythe J et al (1992) Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 339(8792):530–533PubMedCrossRefGoogle Scholar
  69. Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ (2012) Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry 69(8):787–794PubMedPubMedCentralCrossRefGoogle Scholar
  70. Jones I, Heron J, Robertson E (2010) Puerperal psychosis. In: Kohen D (ed) Women and mental health. Oxford University Press, Oxford, pp 179–186Google Scholar
  71. Kallen B, Olausson PO (2008) Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17(8):801–806PubMedCrossRefGoogle Scholar
  72. Kallen B, Otterblad Olausson P (2006) Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 21(3):221–222PubMedCrossRefGoogle Scholar
  73. Kallen BA, Otterblad Olausson P (2007) Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79(4):301–308PubMedCrossRefGoogle Scholar
  74. Kendell RE, Chalmers JC, Platz C (1987) Epidemiology of puerperal psychoses. Br J Psychiatry 150:662–673PubMedCrossRefGoogle Scholar
  75. Khalifeh H, Dolman C, Howard LM (2015) Safety of psychotropic drugs in pregnancy. BMJ 350:h2260PubMedCrossRefGoogle Scholar
  76. Khazaie H, Ghadami MR, Knight DC, Emamian F, Tahmasian M (2013) Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. Psychiatry Res 210(3):901–905PubMedCrossRefGoogle Scholar
  77. Kieler H, Artama M, Engeland A, Ericsson O, Furu K, Gissler M, Nielsen RB, Norgaard M, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B (2012) Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344:d8012PubMedCrossRefGoogle Scholar
  78. Klinger G, Stahl B, Fusar-Poli P, Merlob P (2013) Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev 10(3):308–317PubMedGoogle Scholar
  79. Li D, Liu L, Odouli R (2009) Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum Reprod 24(1):146–153PubMedCrossRefGoogle Scholar
  80. Lin AE, Peller AJ, Westgate MN, Houde K, Franz A, Holmes LB (2004) Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res A Clin Mol Teratol 70(8):534–536PubMedCrossRefGoogle Scholar
  81. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA (2007) First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356(26):2675–2683PubMedCrossRefGoogle Scholar
  82. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, Kalayjian LA, Kanner A, Liprace JD, Pennell PB, Privitera M, Loring DW, Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) Study Group (2014) Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr 168:729–736PubMedPubMedCentralCrossRefGoogle Scholar
  83. Molgaard-Nielsen D, Hviid A (2011) Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305(19):1996–2002PubMedCrossRefGoogle Scholar
  84. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL (2005) Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293(19):2372–2383PubMedCrossRefGoogle Scholar
  85. Mosher WD, Bachrach CA (1996) Understanding U.S. fertility: continuity and change in the National Survey of Family Growth, 1988–1995. Fam Plann Perspect 28(1):4–12PubMedCrossRefGoogle Scholar
  86. Nakhai-Pour HR, Broy P, Berard A (2010) Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182(10):1031–1037PubMedPubMedCentralCrossRefGoogle Scholar
  87. Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH (2008) Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 192(5):333–337PubMedCrossRefGoogle Scholar
  88. Newport DJ, Levey LC, Pennell PB, Ragan K, Stowe ZN (2007) Suicidal ideation in pregnancy: assessment and clinical implications. Arch Womens Ment Health 10(5):181–187PubMedCrossRefGoogle Scholar
  89. Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hultman CM (2002) Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res 58(2–3):221–229PubMedCrossRefGoogle Scholar
  90. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, Kulin N, Koren G (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336(4):258–262PubMedCrossRefGoogle Scholar
  91. O’Brien L, Einarson TR, Sarkar M, Einarson A, Koren G (2008) Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 30(8):696–701PubMedCrossRefGoogle Scholar
  92. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W (2004) Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65(2):230–237PubMedCrossRefGoogle Scholar
  93. Oberlander TF, Gingrich JA, Ansorge MS (2009) Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 86(6):672–677PubMedPubMedCentralCrossRefGoogle Scholar
  94. O'Connor TG, Ben-Shlomo Y, Heron J, Golding J, Adams D, Glover V (2005) Prenatal anxiety predicts individual differences in cortisol in pre-adolescent children. Biol Psychiatry 58(3):211–217PubMedCrossRefGoogle Scholar
  95. Okun ML, Ebert R, Saini B (2015) A review of sleep-promoting medications used in pregnancy. Am J Obstet Gynecol 212(4):428–441PubMedCrossRefGoogle Scholar
  96. Orr ST, Blazer DG, James SA, Reiter JP (2007) Depressive symptoms and indicators of maternal health status during pregnancy. J Womens Health (Larchmt) 16(4):535–542CrossRefGoogle Scholar
  97. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C et al (1993) Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269(17):2246–2248PubMedCrossRefGoogle Scholar
  98. Paton C (2008) Prescribing in pregnancy. Br J Psychiatry 192(5):321–322PubMedCrossRefGoogle Scholar
  99. Pavek P, Ceckova M, Staud F (2009) Variation of drug kinetics in pregnancy. Curr Drug Metab 10(5):520–529PubMedCrossRefGoogle Scholar
  100. Payne JL (2003) The role of estrogen in mood disorders in women. Int Rev Psychiatry 15(3):280–290PubMedCrossRefGoogle Scholar
  101. Payne JL, Meltzer-Brody S (2009) Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol 52(3):469–482PubMedPubMedCentralCrossRefGoogle Scholar
  102. Payne JL, Roy PS, Murphy-Eberenz K, Weismann MM, Swartz KL, McInnis MG, Nwulia E, Mondimore FM, MacKinnon DF, Miller EB, Nurnberger JI, Levinson DF, DePaulo JR Jr, Potash JB (2007) Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 99(1–3):221–229PubMedCrossRefGoogle Scholar
  103. Pearlstein T (2013) Use of psychotropic medication during pregnancy and the postpartum period. Womens Health (Lond Engl) 9(6):605–615CrossRefGoogle Scholar
  104. Peng M, Gao K, Ding Y, Ou J, Calabrese JR, Wu R, Zhao J (2013) Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl) 228(4):577–584CrossRefGoogle Scholar
  105. Rahimi R, Nikfar S, Abdollahi M (2006) Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials. Reprod Toxicol 22(4):571–575PubMedCrossRefGoogle Scholar
  106. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C (2013) Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 346:f2059PubMedPubMedCentralCrossRefGoogle Scholar
  107. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A (2008) Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 192(5):344–350PubMedCrossRefGoogle Scholar
  108. Reis M, Kallen B (2008) Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 28(3):279–288PubMedCrossRefGoogle Scholar
  109. Reis M, Kallen B (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40(10):1723–1733PubMedCrossRefGoogle Scholar
  110. Reis M, Kallen B (2013) Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 2013:3(2)Google Scholar
  111. Robinson GE (2012) Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol 19(3):e380–e386PubMedGoogle Scholar
  112. Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A (2013) Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 70(4):436–443PubMedCrossRefGoogle Scholar
  113. Seeman MV (2004) Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 161(8):1324–1333PubMedCrossRefGoogle Scholar
  114. Seeman MV (2013) Clinical interventions for women with schizophrenia: pregnancy. Acta Psychiatr Scand 127(1):12–22PubMedCrossRefGoogle Scholar
  115. Sharma V (2003) Role of sleep loss in the causation of puerperal psychosis. Med Hypotheses 61(4):477–481PubMedCrossRefGoogle Scholar
  116. Sharma V, Smith A, Khan M (2004) The relationship between duration of labour, time of delivery, and puerperal psychosis. J Affect Disord 83(2–3):215–220PubMedCrossRefGoogle Scholar
  117. Simon GE, Cunningham ML, Davis RL (2002) Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159(12):2055–2061PubMedCrossRefGoogle Scholar
  118. Stewart DE, Klompenhouwer JL, Kendell RE, van Hulst AM (1991) Prophylactic lithium in puerperal psychosis. The experience of three centres. Br J Psychiatry 158:393–397PubMedCrossRefGoogle Scholar
  119. Thiels C (1987) Pharmacotherapy of psychiatric disorder in pregnancy and during breastfeeding: a review. Pharmacopsychiatry 20(4):133–146PubMedCrossRefGoogle Scholar
  120. Tracy TS, Venkataramanan R, Glover DD, Caritis SN (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 192(2):633–639PubMedCrossRefGoogle Scholar
  121. van Gent EM, Verhoeven WM (1992) Bipolar illness, lithium prophylaxis, and pregnancy. Pharmacopsychiatry 25(4):187–191PubMedCrossRefGoogle Scholar
  122. Vigod SN, Gomes T, Wilton AS, Taylor VH, Ray JG (2015) Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ 350:h2298PubMedPubMedCentralCrossRefGoogle Scholar
  123. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ (2000) Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 157(2):179–184PubMedCrossRefGoogle Scholar
  124. Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS (2007) Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 164(12):1817–1824, quiz 1923PubMedCrossRefGoogle Scholar
  125. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, Verter J, Stoll BJ, Lemons JA, Papile LA, Shankaran S, Donovan EF, Oh W, Ehrenkranz RA, Fanaroff AA (2000) Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105(1 Pt 1):14–20PubMedCrossRefGoogle Scholar
  126. Webb RT, Howard L, Abel KM (2004) Antipsychotic drugs for non-affective psychosis during pregnancy and postpartum. Cochrane Database Syst Rev 2:CD004411Google Scholar
  127. Webster PA (1973) Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2(7824):318–319PubMedCrossRefGoogle Scholar
  128. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ (2009) Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 84(1):23–27PubMedPubMedCentralCrossRefGoogle Scholar
  129. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG (2011) Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 28(1):19–24PubMedCrossRefGoogle Scholar
  130. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C (2009) The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31(5):403–413PubMedPubMedCentralCrossRefGoogle Scholar
  131. Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N, Luchansky E, Lin H, Belanger K (2012) Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 23(5):677–685PubMedPubMedCentralCrossRefGoogle Scholar
  132. Yonkers KA, Blackwell KA, Glover J, Forray A (2014) Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol 10:369–392PubMedCrossRefGoogle Scholar
  133. Zuckerman B, Amaro H, Bauchner H, Cabral H (1989) Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 160(5 Pt 1):1107–1111PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland (outside the USA)  2016

Authors and Affiliations

  1. 1.Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations